Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

NCT05392751 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.

Conditions

Interventions

Sponsor

Endogena Therapeutics, Inc